Evaluation of the Abuse Liability of Very Low Nicotine (VLN) Cigarettes

Evaluation of the Abuse Liability of Very Low Nicotine (VLN) Cigarettes With Characterization of Nicotine Exposure Profiles in Adult Smokers

This study is designed to evaluate the abuse liability of very low nicotine cigarettes compared to nicotine gum and usual brand cigarettes

Study Overview

• Status: Completed
• Conditions: Tobacco Use
• Intervention / Treatment: Drug: Nicotine gum (C); Other: Usual Brand Cigarettes (B); Other: VLN cigarettes (A)

Detailed Description

This study will be a randomized, two-part, 3-way crossover designed to evaluate the abuse liability, pharmacokinetics (PK), and product use behavior associated with study products, including VLN cigarettes, subjects' own-brand cigarettes, and nicotine polacrilex gum in healthy adult male and female exclusive smokers. Subjects will participate in a standard Screening visit and one 7-day Confined Assessment Phase, which will include a product trial session (Day -1), and two study parts (Part A and Part B). Following the Screening visit, eligible subjects will check-in to the study site on Day -1. Following the polacrilex gum training session, subjects will be required to abstain from nicotine- and tobacco-containing products for approximately 20 hours until the first product use session on Days 1 to 3; use of other nicotine-containing products will be prohibited throughout the study. No additional tobacco or nicotine products will be provided after the second product use on Days 4 to 6.

On Day 1, subjects will be randomized to one of three product sequence groups in Part A, which will consist of an ad libitum product use session for each of the following study products for 4 hours in a randomized crossover manner (Days 1 to 3; one product per day):

Product A: VLN cigarette

Product B: Own-brand filtered standard king size cigarette

Product C: 4 mg Nicotine polacrilex gum

A pharmacodynamic measure ("use product again" Visual Analog Scale (VAS)) will be administered at the end of each ad libitum product use period. Product use behaviors (i.e., number of units consumed,duration of gum in mouth) will be collected throughout each ad libitum product use period. Upon completion of Part A, subjects will be randomized to one of three product sequence groups in Part B, which will consist of 3 study days (Days 4 to 6), with one product per day. Each study day will consist of: 1) Controlled Product Use Session (10 puffs from their own-brand cigarette or VLN cigarette [maximum 3 ± 2 seconds per puff] at approximately 30 ± 5-second interpuff intervals, or chew the nicotine polacrilex gum using the "chew and park" method for 10 minutes); and 2) Uncontrolled Product Use Session (ad libitum use for 10 minutes). The Controlled Product Use Session and Uncontrolled Product Use Session will be separated by approximately 6 hours. During Part B, pharmacodynamic measures, PK, and product use behavior (Uncontrolled only) will be collected at various time points each day.

• Study Type: Interventional
• Enrollment (Actual): 66
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Kansas
    • Overland Park, Kansas, United States, 66212
      • Vince & Associates Clinical Research, Inc

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 22 years to 65 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

Subjects will be required to meet each one of the following inclusion criteria in order to be eligible for participation in the study:

1. Must provide written informed consent prior to the initiation of any protocol-specific procedures.
2. Male and female adults, between 22 to 65 years of age, inclusive.
3. Body mass index (BMI) within 18.0 to 35.0 kg/m2, inclusive (minimum weight of at least 50.0 kg at Screening).
4. Healthy, as determined by no clinically significant medical history, physical examination, 12-lead ECG, vital signs or laboratory (including hematology, clinical chemistry, urinalysis, and serology) findings at Screening, as judged by an investigator.
5. Smoking history of an average of at least 10 manufactured filtered standard (i.e., not slim) king size combustible cigarettes daily for at least 1 year prior to Screening. Brief periods (i.e., up to 7 consecutive days) of non-smoking during the 3 months prior to Screening (e.g., due to illness or participation in a study where smoking was prohibited) will be permitted.
6. Self-reporting of desire to smoke within approximately 30 minutes of waking.
7. Positive urine cotinine (≥500 ng/mL) at Screening.
8. Negative pregnancy test at Screening and Day -1 (check-in) for all female subjects.
9. Female subjects of non-childbearing potential must be surgically sterile or 1 year postmenopausal (as confirmed by serum Follicle Stimulating Hormone (FSH) > 35 U/L). A subject is considered to be surgically sterile if she has had a tubal ligation, hysterectomy, bilateral salpingo-oophorectomy or bilateral oophorectomy, or hysterectomy with bilateral salpingo-oophorectomy. If the subject is of childbearing potential, she must be using a medically accepted method of contraception and agree to continued use of this method for the duration of the study and for 30 days after completion of the study. Acceptable methods of contraception include abstinence, birth control pill, or an intrauterine device (known to have a failure rate of less than 1% per year) or double barrier method of contraception (e.g., male condom in addition to a diaphragm, contraceptive sponge or spermicide).
10. Able to speak, read, and understand English sufficiently to allow completion of all study assessments.
11. Must be willing to comply with the requirements and restrictions of the study.

Exclusion Criteria:

Subjects will not be eligible to participate in this study if any one of the following exclusion criteria is met:

1. Inability to tolerate 4 mg nicotine polacrilex gum during product use trial on Day -1 (check-in) or dentition prevents subjects from chewing gum.
2. History or presence of any clinically significant cardiac, psychiatric, endocrine, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, renal, or other major disease at Screening, which in the opinion of an investigator would jeopardize the safety of the subject or the validity of the study results.
3. History or presence of any type of malignant tumors.
4. Clinically significant abnormal findings on the vital signs, physical examination (including oral exam), medical history, or clinical laboratory results, in the opinion of an investigator.
5. Positive serology test results for human immunodeficiency virus (HIV-1/HIV-2) Antibodies, hepatitis B surface antigen (HbsAg), or hepatitis C Antibody (HCVAb).
6. An acute illness (e.g., upper respiratory infection, viral infection) requiring treatment within 2 weeks prior to Day -1 (check-in).
7. Drug or alcohol abuse or dependence within the 24 months prior to Screening (except nicotine), as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition text revision (DSM-IV-TR), or any self-reported dependence or "addiction" within the subject's lifetime (except nicotine or caffeine).
8. Subjects who have ever been in treatment for substance use disorder(s) or who are currently
9. Positive urine drug screen (UDS) or urine alcohol test at Screening or Day -1 (check-in).
10. History or any current conditions that may interfere with drug absorption, distribution, metabolism, or excretion.
11. History of severe allergic reaction (including anaphylaxis) to any substance, or previous status asthmaticus, or food allergies/intolerances/restrictions, or special dietary needs which, in the judgment of an investigator, contraindicates the subject's participation in the study.
12. Requires concomitant treatment with prescription or non-prescription products that contain pseudoephedrine (e.g., nasal/sinus decongestants).
13. Self-reported use of nicotine polacrilex gum, or other nicotine replacement therapy products in the 30 days prior to Day -1 (check-in). Isolated incidents within 30 days prior to Day -1 (check-in) may be permitted at the discretion of the investigator.
14. Subject has unsuitable or difficult venous access or is unwilling or unable to undergo direct venipuncture or catheter insertion.
15. Subject has donated or lost 100 to 499 mL whole blood within 30 days or more than 499 mL whole blood within 56 days preceding entry into the Confined Assessment Phase.
16. Subject is an employee of the sponsor or research site personnel directly affiliated with this study or their immediate family member defined as a spouse, parent, child or sibling, whether biological or legally adopted.
17. Subject is lactating and or breast feeding.
18. A subject who, in the opinion of an investigator, is considered unsuitable or unlikely to comply with the study protocol for any reason.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: OTHER
• Allocation: RANDOMIZED
• Interventional Model: CROSSOVER
• Masking: NONE

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: VLN Cigarettes (A); Subjects will smoke VLN cigarettes	Drug: Nicotine gum (C); 4 mg nicotine gum; Other: Usual Brand Cigarettes (B); Usual brand king size non-menthol cigarettes
EXPERIMENTAL: Usual Brand Cigarettes (B); Subjects will smoke their usual brand cigarettes	Drug: Nicotine gum (C); 4 mg nicotine gum; Other: VLN cigarettes (A); 0.4mg nicotine / g tobacco king size filter cigarette
EXPERIMENTAL: Nicotine Gum (C); Subjects will chew nicotine gum	Other: Usual Brand Cigarettes (B); Usual brand king size non-menthol cigarettes; Other: VLN cigarettes (A); 0.4mg nicotine / g tobacco king size filter cigarette

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Emax_urge(controlled)	The maximum reduction in Visual Analog Scale (VAS) score for the question "Urges to smoke" (Tobacco/Nicotine Withdrawal Questionnaire) between pre-use and post-use (i.e., VASpre-use1 - VASpost-use1) during the first product use in Part B.	3 days - administered at the end of each product use session (Use of each product on a different day)
Emax_plst(controlled)	The largest VAS score recorded for the response to the question "Is the product "Pleasant" right now?" (Direct Effects of Product Questionnaire) during the first product use in Part B.	3 days - administered at the end of each product use session (Use of each product on a different day)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Emax_anx (Uncontrolled)	The largest VAS score recorded for the response to "Anxious" (Tobacco/nicotine withdrawal questionnaire) during the product use in Uncontrolled Section of Part B.	pre, 5, 15, 30, 60, and 90 minutes
Emax_diffct (Controlled)	The largest VAS score recorded for the response to "Difficulty Concentrating" (Tobacco/nicotine withdrawal questionnaire) during the product use in Controlled Section of Part B.	pre, 5, 15, 30, 60, and 90 minutes
Emax_impat (Controlled)	The largest VAS score recorded for the response to "Impatient" (Tobacco/nicotine withdrawal questionnaire) during the product use in Controlled Section of Part B.	pre, 5, 15, 30, 60, and 90 minutes
Emax_impat (Uncontrolled)	The largest VAS score recorded for the response to "Impatient" (Tobacco/nicotine withdrawal questionnaire) during the product use in Uncontrolled Section of Part B.	pre, 5, 15, 30, 60, and 90 minutes
Emax_crav (Controlled)	The largest VAS score recorded for the response to "Craving a Cigarette" (Tobacco/nicotine withdrawal questionnaire) during the product use in Controlled Section of Part B.	pre, 5, 15, 30, 60, and 90 minutes
Emax_crav (Uncontrolled)	The largest VAS score recorded for the response to "Craving a Cigarette" (Tobacco/nicotine withdrawal questionnaire) during the product use in Uncontrolled Section of Part B.	pre, 5, 15, 30, 60, and 90 minutes
Emax_plas (Uncontrolled)	The largest VAS score recorded for the response to "Pleasant" (Direct effects of product questionnaire) during the product use in Uncontrolled Section of Part B.	pre, 5, 15, 30, 60, and 90 minutes
Emax_stf (Uncontrolled)	The largest VAS score recorded for the response to "Satisfying" (Direct effects of product questionnaire) during the product use in Uncontrolled Section of Part B.	pre, 5, 15, 30, 60, and 90 minutes
Emax_stf (Controlled)	The largest VAS score recorded for the response to "Satisfying" (Direct effects of product questionnaire) during the product use in Controlled Section of Part B.	pre, 5, 15, 30, 60, and 90 minutes
Emax_calm (Uncontrolled)	The largest VAS score recorded for the response to "Calm" (Direct effects of product questionnaire) during the product use in Controlled Section of Part B.	pre, 5, 15, 30, 60, and 90 minutes
Emax_calm (Controlled)	The largest VAS score recorded for the response to "Calm" (Direct effects of product questionnaire) during the product use in Uncontrolled Section of Part B.	pre, 5, 15, 30, 60, and 90 minutes
Emax_conc (Uncontrolled)	The largest VAS score recorded for the response to "Concentrate" (Direct effects of product questionnaire) during the product use in Uncontrolled Section of Part B.	pre, 5, 15, 30, 60, and 90 minutes
Emax_conc (controlled)	The largest VAS score recorded for the response to "Concentrate" (Direct effects of product questionnaire) during the product use in controlled Section of Part B.	pre, 5, 15, 30, 60, and 90 minutes
Emax_awake (Uncontrolled)	The largest VAS score recorded for the response to "Awake" (Direct effects of product questionnaire) during the product use in Uncontrolled Section of Part B.	pre, 5, 15, 30, 60, and 90 minutes
Emax_sick (Uncontrolled)	The largest VAS score recorded for the response to "Sick" (Direct effects of product questionnaire) during the product use in Uncontrolled Section of Part B.	pre, 5, 15, 30, 60, and 90 minutes
Emax_sick (Controlled)	The largest VAS score recorded for the response to "Sick" (Direct effects of product questionnaire) during the product use in Controlled Section of Part B.	pre, 5, 15, 30, 60, and 90 minutes
Emax_hunger (Uncontrolled)	The largest VAS score recorded for the response to "Hunger" (Direct effects of product questionnaire) during the product use in Uncontrolled Section of Part B.	pre, 5, 15, 30, 60, and 90 minutes
Emax_hunger (Controlled)	The largest VAS score recorded for the response to "Hunger" (Direct effects of product questionnaire) during the product use in Controlled Section of Part B.	pre, 5, 15, 30, 60, and 90 minutes
Emax_more (Uncontrolled)	The largest VAS score recorded for the response to "More" (Direct effects of product questionnaire) during the product use in Uncontrolled Section of Part B.	pre, 5, 15, 30, 60, and 90 minutes
Emax_more (Controlled)	The largest VAS score recorded for the response to "More" (Direct effects of product questionnaire) during the product use in Controlled Section of Part B.	pre, 5, 15, 30, 60, and 90 minutes
Inhalations	Number of product inhalations (cigarettes only) during uncontrolled use sessions	3 product use days (Use of each product on a different day)
Puff durations	Duration of inhalations (cigarettes only) during uncontrolled use sessions	2 product use days (Use of each product on a different day)
Gum durations	Duration of gum in mouth during uncontrolled use sessions	1 product use day
Use Product Again	The VAS score recorded for the response to "Use Product Again" (Use product again questionnaire) during the ad libitum product use in Part A.	1 product use day
Cmax(controlled); Maximum Nicotine Concentration	Maximum measured plasma nicotine concentration during the Controlled Use Session.	Pre, 2,5,7,10,12,15,20,30,45,60,90,120,150 ,and 180 minutes
T1/2(controlled); Terminal Half Life	Apparent first-order terminal nicotine elimination half-life calculated as 0.693/Kel of the plasma concentration-time curve from time zero (defined as the start of controlled use) to 180 minutes	Pre, 2,5,7,10,12,15,20,30,45,60,90,120,150 ,and 180 minutes
Kel(controlled); Elimination Rate Constant	Apparent first-order terminal nicotine elimination rate constant calculated from a semi-log plot of the plasma concentration-time curve of the Controlled Use Session.	Pre, 2,5,7,10,12,15,20,30,45,60,90,120,150 ,and 180 minutes
Tmax(controlled); Maximum Time	Time of the maximum measured plasma nicotine concentration during the Controlled Use Session.	Pre, 2,5,7,10,12,15,20,30,45,60,90,120,150 ,and 180 minutes
AUC(controlled); Area under the nicotine concentration-time curve	Area under the nicotine concentration-time curve calculated using linear trapezoidal summation from time zero (defined as the start of controlled use) to 180 minutes (or the last quantifiable concentration during that interval).	Pre, 2,5,7,10,12,15,20,30,45,60,90,120,150 ,and 180 minutes
Cmax(uncontrolled); Maximum Nicotine Concentration	Maximum measured plasma nicotine concentration during the Uncontrolled Use Session.	Pre, 2,5,7,10,12,15,20,30,45,60,90,120,150 ,and 180 minutes
T1/2(uncontrolled); Terminal Half Life	Apparent first-order terminal nicotine elimination half-life calculated as 0.693/Kel of the plasma concentration-time curve from time zero (defined as the start of uncontrolled use) to 540 minutes.	Pre, 2,5,7,10,12,15,20,30,45,60,90,120,150 ,and 180 minutes
Kel(uncontrolled); Elimination Rate Constant	Apparent first-order terminal nicotine elimination rate constant calculated from a semi-log plot of the plasma concentration-time curve of the Controlled Use Session.	Pre, 2,5,7,10,12,15,20,30,45,60,90,120,150 ,and 180 minutes
Tmax(uncontrolled); Maximum Time	Time of the maximum measured plasma nicotine concentration during the Uncontrolled Use Session.	Pre, 2,5,7,10,12,15,20,30,45,60,90,120,150 ,and 180 minutes
AUC(uncontrolled); Area under the nicotine concentration-time curve	Area under the nicotine concentration-time curve calculated using linear trapezoidal summation from time 360 (defined as the start of uncontrolled use) to 540 minutes (or the last quantifiable concentration during that interval).	Pre, 2,5,7,10,12,15,20,30,45,60,90,120,150 ,and 180 minutes
Emax_urge (Uncontrolled)	The largest VAS score recorded for the response to "Urges to Smoke" (Tobacco/nicotine withdrawal questionnaire) during the product use in Uncontrolled Section of Part B.	pre, 5, 15, 30, 60, and 90 minutes
Emax_anx (Controlled)	The largest VAS score recorded for the response to "Anxious" (Tobacco/nicotine withdrawal questionnaire) during the product use in Controlled Section of Part B.	pre, 5, 15, 30, 60, and 90 minutes
Emax_diffct (Uncontrolled)	The largest VAS score recorded for the response to "Difficulty Concentrating" (Tobacco/nicotine withdrawal questionnaire) during the product use in Uncontrolled Section of Part B.	pre, 5, 15, 30, 60, and 90 minutes
Emax_awake (controlled)	The largest VAS score recorded for the response to "Awake" (Direct effects of product questionnaire) during the product use in controlled Section of Part B.	pre, 5, 15, 30, 60, and 90 minutes

Collaborators and Investigators

• Sponsor: 22nd Century Group, Inc.
• Collaborators: Vince & Associates Clinical Research, Inc.

Study record dates

Study Major Dates

• Study Start (ACTUAL): April 13, 2018
• Primary Completion (ACTUAL): September 6, 2018
• Study Completion (ACTUAL): September 6, 2018

Study Registration Dates

• First Submitted: May 23, 2018
• First Submitted That Met QC Criteria: June 14, 2018
• First Posted (ACTUAL): June 18, 2018

Study Record Updates

• Last Update Posted (ACTUAL): March 26, 2020
• Last Update Submitted That Met QC Criteria: March 24, 2020
• Last Verified: March 1, 2020

More Information

Terms related to this study

• Keywords: Abuse liability
• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Autonomic Agents; Peripheral Nervous System Agents; Cholinergic Agents; Ganglionic Stimulants; Nicotinic Agonists; Cholinergic Agonists; Nicotine
• Other Study ID Numbers: CEG-P9-153

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No